Abstract
This is the second of a series of continuing education articles on radiopharmaceuticals. After reading and studying this article, the nuclear medicine technologist will be able to: (1) identify the clinical utility of each new radiopharmaceutical described; and (2) discuss technical considerations, such as amount of activity administered, imaging times, radiation dosage, and pitfalls of each. New radiotracers will play an important role in the future of nuclear medicine. This article discusses the technical aspects and potential clinical efficacy of three new radiotracers: gold-195m, iodine-123 amphetamines, and technetium-99m DTPA aerosols.
Footnotes
↵* Current address: Emory University Hospital, Atlanta, GA.